Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

Pfizer900 enrolled

Overview

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias

For additional information please call: 1-800-718-1021

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

900

Conditions

Hyperlipidemia

Interventions

torcetrapib/atorvastatinDRUG

atorvastatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Statin eligible per NCEP ATP-III guidelines * At least 18 years of age Exclusion Criteria: * Women who are pregnant or lactating, or planning to become pregnant * Intolerance to statin therapy * Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors * Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Locations (59)

Outcomes

Primary Outcomes

Change in lipid parameters (HDL, LDL) at various timepoints over 12 months.

Secondary Outcomes

Changes in levels of lipids and other biomarkers.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Huntsville, Alabama, United States

Pfizer Investigational Site

Union Grove, Alabama, United States

Pfizer Investigational Site

Fresno, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Orange, California, United States

Pfizer Investigational Site

San Diego, California, United States

Pfizer Investigational Site

Denver, Colorado, United States

Pfizer Investigational Site

Denver, Colorado, United States

Pfizer Investigational Site

Golden, Colorado, United States

Pfizer Investigational Site

Bridgeport, Connecticut, United States

...and 49 more locations